Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 20/20 | 0.53 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.53 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.44 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.44 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21258682 | 0.94 | PTGIR (0.51) | PTGIRPTGDRPTGER4PTGER3PTGER2 | |
| SCHEMBL21258909 | 0.93 | PTGIR (0.53) | PTGIRPTGDRPTGER4PTGER3PTGER2 | |
| SCHEMBL21258864 | 0.92 | PTGIR (0.54) | PTGIRPTGDRPTGER4PTGER3PTGER2 | |
| SCHEMBL21258658 | 0.91 | PTGIR (0.54) | PTGIRPTGDRPTGER4PTGER3PTGER2 | |
| SCHEMBL21258974 | 0.91 | PTGIR (0.53) | PTGIRPTGDRPTGER4PTGER3PTGER2 | |
| SCHEMBL21258944 | 0.89 | PTGIR (0.55) | PTGIRPTGDR | |
| SCHEMBL21258912 | 0.89 | PTGIR (0.42) | PTGIRPTGDR | |
| SCHEMBL21258991 | 0.88 | PTGIR (0.43) | PTGIRPTGDR | |
| SCHEMBL21258855 | 0.88 | PTGIR (0.49) | PTGIRPTGDR | |
| SCHEMBL21258856 | 0.86 | PTGIR (0.53) | PTGIRPTGDRPTGER4PTGER3PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338665-A1 | MEDICAL USE OF PROSTACYCLIN RECEPTOR AGONIST | CHINESE PLA GENERAL HOSPITAL (CN) | 2021-11-04 | — | — | US | disclosed |
| US-20210087168-A1 | PROSTACYCLIN RECEPTOR AGONIST | MEDSHINE DISCOVERY INC. (CN) | 2021-03-25 | — | — | US | disclosed |
| EP-3750879-A1 | PROSTACYCLIN RECEPTOR AGONIST | Medshine Discovery Inc. (CN) | 2020-12-16 | — | — | EP | disclosed |
| WO-2019154363-A1 | PROSTACYCLIN RECEPTOR AGONIST | 南京明德新药研发有限公司 | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087168-A1 | PROSTACYCLIN RECEPTOR AGONIST | PTGIR, TBXA2R, PTGFR | PTGIR 1/4885PTGDR 9/4885PTGER4 24/4885 |
| US-20210338665-A1 | MEDICAL USE OF PROSTACYCLIN RECEPTOR AGONIST | PTGIR, CYP11B2, PDE8A | PTGIR 1/4885PTGDR 29/4885PTGER4 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.